Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy
About this episode
The episode features an interview with Dr. Michael A. Postow discussing the outcomes of melanoma brain metastases after anti-PD-1 therapy.
Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
More episodes of JAMA Oncology Author Interviews
- Metastatic Recurrence Among Adolescents and Young Adults With Cancer
- Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality
- Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer
- Proportional Sedation for Persistent Agitated Delirium in Palliative Care
- New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
- Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
Explore listener stats, chart rankings, contacts and more on the JAMA Oncology Author Interviews podcast page.